A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia

Published:2013-07-12 Issue:2 Volume:98 Page:164-170
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Ogawa Yoshiaki,Ogura Michinori,Suzuki Tatsuya,Ando Kiyoshi,Uchida Toshiki,Shirasugi Yukari,Tobinai Kensei,Lee Je Hwan,Kase Masazumi,Katsura Koichi,Hotta Tomomitsu

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/content/pdf/10.1007/s12185-013-1393-x.pdf

Reference15 articles.

1. Teeling JL, French RR, Cragg MS, von den Brakel JH, Pluyter M, Huang H, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104:1793–800.

2. Teeling JL, Mackus WJ, Wiegman LJ, von den Brakel JH, Beers SA, French RR, et al. The biological activity of human CD monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177:362–71.

3. Beum PV, Lindorfer MA, Beurskens F, Stukenberg PT, Lokhorst HM, Pawluczkowycz AW, et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J Immunol. 2008;181:822–32.

4. Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewsk J, Hellmann A, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008;111:5486–95.

5. Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. J Clin Oncol. 2010;28:3525–30.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of Ruxolitinib on fibrosis in preclinical models of systemic sclerosis;International Immunopharmacology;2023-03

2. Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation;Acta Haematologica;2021-09-20

3. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma;International Journal of Hematology;2020-10-23

4. Pros and cons of the immunogenicity of monoclonal antibodies in cancer treatment: a lesson from autoimmune diseases;Immunotherapy;2019-02

5. Ibrutinib versus rituximab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma: a randomized, open-label phase 3 study;Cancer Medicine;2018-03-13